FTC’s Critical Meeting Puts AbbVie’s $8.7 Billion Cerevel Deal in the Spotlight

Cerevel Therapeutics (NASDAQ:CERE) shares fluctuated amid concerns about the FTC's closed-door meeting potentially affecting AbbVie's planned $8.7 billion acquisition of the company.



